Xbrane announces sales target for the company’s lead product Xlucane

English IR mfn-ca mfn-ca-other mfn-regulatory-mar Press Release Regulatory

Solna, Sweden – Xbrane Biopharma recently initiated the phase III trial in the US with Xlucane, a ranibizumab (Lucentis®) biosimilar candidate. Xlucane’s co-development and commercialization partner is the German pharmaceuticals company Stada Arzneimittel AG with more than 10,400 employees worldwide. Xbrane expects the first revenues from Xlucane sales during the first quarter 2022.

Xbrane announces sales target for the company’s lead product Xlucane

Solna, Sweden Xbrane Biopharma recently initiated the phase III trial in the US with Xlucane, a ranibizumab (Lucentis®) biosimilar candidate. Xlucane’s co-development and commercialization partner is the German pharmaceuticals company Stada Arzneimittel AG with more than 10,400 employees worldwide. Xbrane expects the first revenues from Xlucane sales during the first quarter 2022.

The following sales target have been adopted:

  • Xbrane’s target is to reach €350 million in annual net sales three years after the product launch. This renders approximately €100 million in annual license income for Xbrane, after deduction of production and sales related expenses and profit sharing with STADA.

The sales target is based on reaching a volume market share of 25% in Europe and US of the current (2018) Lucentis® (ranibizumab) market at a price discount in line with recent biosimilar product launches. During 2018 Lucentis® global sales amounted to €3.5 billion.

“We strongly believe in the commercial prospects of Xlucane. There is a great need for more cost-efficient products in the ophthalmic VEGFa inhibitor market and I am confident that Xlucane *will be received positively by the ophthalmology community and patients,*” said Martin Åmark, CEO Xbrane.

“We are convinced of Xbranes capabilities to bring Xlucane successful and on time through development and registration. We see strong sales potential of the product in Europe and in the US. *Our leading positions in a lot of European markets make us confident to capture a sizable share of the market,*” said Peter Goldschmidt, CEO STADA.

CEO Martin Åmark and Chairman Anders Tullgren will present additional details and host a Q&A session on April 23 at 9:30.

To attend, please use call in details and follow the link below:

https://financialhearings.com/event/12055

SE: +46850558354
UK: +443333009032

About Xbrane
Xbrane Biopharma AB is a biotechnology company which develops, manufactures and produces commercial biosimilars. Xbrane has a patented protein production platform for development of biosimilars and world-leading expertise within biosimilars. Xbrane’s head quarter is located in Solna, outside Stockholm, and the company has research and development facilities in Sweden and in Italy. Xbrane has been listed on Nasdaq First North since 3 February 2016 with the ticker XBRANE. Avanza Bank AB (corp@avanza.se, +46 (0)8 409 421 20) is Xbrane’s Certified Adviser. For more information see www.xbrane.com.

About STADA
STADA Arzneimittel AG is a publicly-listed company with headquarters in Bad Vilbel, Germany. The company focuses on a three-pillar strategy consisting of generics, non-prescription OTC products and specialty pharmaceuticals, biosimilars in particular. Worldwide, STADA is represented in about 30 countries with roughly 50 subsidiaries. Branded products such as Grippostad and Ladival are among the highest selling in their product categories in Germany. In financial year 2018, STADA achieved adjusted Group sales of Euro 2,330.8 million, adjusted earnings before interest, taxes, depreciation and amortization (EBITDA) of Euro 530.6 million. As per December 31, 2018, STADA employed 10,416 people worldwide.